Neoprobe (NEOP -10.2%) fell sharply in afternoon trading on rumors an application for its...

|By:, SA News Editor

Neoprobe (NEOP -10.2%) fell sharply in afternoon trading on rumors an application for its Lymphoseek cancer-detection drug was rejected. However, shares are up 5.8% AH after a spokesperson says Neoprobe isn't aware of any news about its application, which the FDA is expected to decide upon by Oct. 24.